These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 29465464)

  • 1. Immunostimulating and cancer-reductive experimental therapy with the oxazaphosphorine cytostatic SUM-IAP.
    Voelcker G
    Anticancer Drugs; 2018 Jun; 29(5):411-415. PubMed ID: 29465464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of antitumor activity of the oxazaphosphorine cytostatic SUM-IAP by N-methylformamide.
    Voelcker G
    J Cancer Res Clin Oncol; 2016 Jun; 142(6):1183-9. PubMed ID: 26941190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased antitumour activity of mesyl-I-aldophosphamide-perhydrothiazine, in vivo but not in vitro, compared to I-aldophosphamide-perhydrothiazine.
    Voelcker G; Pfeiffer B; Schnee A; Hohorst H
    J Cancer Res Clin Oncol; 2000 Feb; 126(2):74-8. PubMed ID: 10664245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of the alkylating function of aldo-Ifosfamide on the anti-tumor activity.
    Voelcker G
    Anticancer Drugs; 2018 Jan; 29(1):75-79. PubMed ID: 29219879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldophosphamide-thiazolidine (NSC-613060) an oxazaphosphorine cytostatic that crosses the blood brain barrier.
    Voelcker G
    Anticancer Drugs; 2021 Jan; 32(1):61-65. PubMed ID: 32701559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxazaphosphorine cytostatics: from serendipity to rational drug design.
    Voelcker G
    Anticancer Drugs; 2019 Jun; 30(5):435-440. PubMed ID: 30855309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin.
    Jones B; Komarnitsky P; Miller GT; Amedio J; Wallner BP
    Anticancer Drugs; 2012 Feb; 23(2):173-84. PubMed ID: 22027537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiazolidinyl- and perhydrothiazinylphosphamidesters: toxicity and preliminary antitumour evaluation.
    Voelcker G; Bielicki L; Hohorst HJ
    J Cancer Res Clin Oncol; 1997; 123(11-12):623-31. PubMed ID: 9620221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Research on therapeutic effects of bufonis venenum on L7212 leukemia and its mechanism].
    Xiao Y; Xue QF
    Zhong Yao Cai; 2014 Feb; 37(2):199-201. PubMed ID: 25095334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effect of 3-[3-(2-chloroethyl)-3-nitrosoureido]-3-deoxy-D-glucopyranose on murine tumors.
    Komiyama K; Edanami K; Kuroda T; Umezawa I
    Gan; 1981 Feb; 72(1):53-9. PubMed ID: 6456168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity and bone marrow toxicity of aminoglucose mustard anticancer agents in mice.
    Cantrell JE; Green D; Schein PS
    Cancer Res; 1986 May; 46(5):2340-3. PubMed ID: 2938728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological properties of racemic chlorobromofosfamide.
    Juszkiewicz M; Kleinrok Z; Sawiniec Z
    Arch Immunol Ther Exp (Warsz); 1994; 42(5-6):405-13. PubMed ID: 8572900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of 1-aldofosfamide-perhydrothiazines.
    Zimmermann J; Bauer HH; Hohorst HJ; Voelcker G
    Arzneimittelforschung; 2000 Sep; 50(9):843-7. PubMed ID: 11050703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
    Borden EC; Sidky YA; Hatcher JF; Bryan GT
    Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotoxic, cytostatic, antineoplastic and apoptotic effects of newly synthesized antitumour steroidal esters.
    Karapidaki I; Bakopoulou A; Papageorgiou A; Iakovidou Z; Mioglou E; Nikolaropoulos S; Mourelatos D; Lialiaris T
    Mutat Res; 2009 Apr; 675(1-2):51-9. PubMed ID: 19386248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Separation and pharmaco-toxicological studies of the enantiomers of Ifosfamide].
    Blaschke G; Hilgard P; Maibaum J; Niemeyer U; Pohl J
    Arzneimittelforschung; 1986 Oct; 36(10):1493-5. PubMed ID: 3814210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application-dependent immunomodulating and antimetastatic efficacy of thymic peptides in BALB/c-mice.
    Beuth J; Schierholz JM; Ko HL; Braun JM
    In Vivo; 2001; 15(5):403-6. PubMed ID: 11695237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic synergism of tiazofurin and selected antitumor drugs against sensitive and resistant P388 leukemia in mice.
    Harrison SD; O'Dwyer PJ; Trader MW
    Cancer Res; 1986 Jul; 46(7):3396-400. PubMed ID: 3708573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement.
    Benzaïd I; Mönkkönen H; Bonnelye E; Mönkkönen J; Clézardin P
    Clin Cancer Res; 2012 Nov; 18(22):6249-59. PubMed ID: 23032740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical studies on NSC290205 aza-steroid alkylator activity in combination with adriamycin against lymphoid leukaemia.
    Trafalis DT; Tsavdaridis D; Camoutsis C; Karayiani V; Mourelatos D; Dalezis P; Athanassiou A; Pangalis GA; Papageorgiou A
    Br J Haematol; 2005 Feb; 128(3):343-50. PubMed ID: 15667536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.